Analysis and Commentary STEVEN GROSSMAN 7/14/23 Analysis and Commentary STEVEN GROSSMAN 7/14/23 FDA and the Threat of Sequester Read More Analysis and Commentary STEVEN GROSSMAN 6/30/23 Analysis and Commentary STEVEN GROSSMAN 6/30/23 The State of FY 24 Appropriations: Four Answers to Not-So-Easy Questions Read More Analysis and Commentary STEVEN GROSSMAN 6/23/23 Analysis and Commentary STEVEN GROSSMAN 6/23/23 Q&A on Senate Appropriations Markup Read More Analysis and Commentary STEVEN GROSSMAN 6/16/23 Analysis and Commentary STEVEN GROSSMAN 6/16/23 Q&A on House Appropriations Markup Read More Analysis and Commentary STEVEN GROSSMAN 6/9/23 Analysis and Commentary STEVEN GROSSMAN 6/9/23 Budget Deal Sets Parameters But Many Unknowns Read More Analysis and Commentary STEVEN GROSSMAN 6/2/23 Analysis and Commentary STEVEN GROSSMAN 6/2/23 The Budget Deal - First Impressions from an FDA Perspective Read More Analysis and Commentary STEVEN GROSSMAN 5/19/23 Analysis and Commentary STEVEN GROSSMAN 5/19/23 The Macro- and Micro- Budget Processes and Their Impact on FDA Resources Read More Analysis and Commentary STEVEN GROSSMAN 5/12/23 Analysis and Commentary STEVEN GROSSMAN 5/12/23 FDA and the Iron Triangle of Deficit Reduction Read More Analysis and Commentary STEVEN GROSSMAN 5/5/23 Analysis and Commentary STEVEN GROSSMAN 5/5/23 Hill Days and the Bumpy FY 24 Appropriations Cycle Read More Analysis and Commentary STEVEN GROSSMAN 4/28/23 Analysis and Commentary STEVEN GROSSMAN 4/28/23 Top Ten Challenges Facing FDA Read More Analysis and Commentary STEVEN GROSSMAN 4/21/23 Analysis and Commentary STEVEN GROSSMAN 4/21/23 Q&A About FDA and the FY 24 Budget/Appropriations Process Read More Analysis and Commentary STEVEN GROSSMAN 4/14/23 Analysis and Commentary STEVEN GROSSMAN 4/14/23 Alliance Testifies to the House and Senate on FY 24 Appropriations Read More Analysis and Commentary STEVEN GROSSMAN 4/6/23 Analysis and Commentary STEVEN GROSSMAN 4/6/23 FDA’s FY 24 Budget Q&A Read More Analysis and Commentary STEVEN GROSSMAN 3/31/23 Analysis and Commentary STEVEN GROSSMAN 3/31/23 Why Participate In Hill Days Read More Analysis and Commentary STEVEN GROSSMAN 3/24/23 Analysis and Commentary STEVEN GROSSMAN 3/24/23 Answers to Your Questions about FY24 Appropriation Read More Analysis and Commentary STEVEN GROSSMAN 3/17/23 Analysis and Commentary STEVEN GROSSMAN 3/17/23 Alliance Seeks Input on FDA Budget Read More Analysis and Commentary STEVEN GROSSMAN 3/10/23 Analysis and Commentary STEVEN GROSSMAN 3/10/23 More Details on the Administration’s FDA Budget Read More Analysis and Commentary STEVEN GROSSMAN 3/3/23 Analysis and Commentary STEVEN GROSSMAN 3/3/23 Looking Ahead to the President’s Budget, Part II Read More Analysis and Commentary STEVEN GROSSMAN 3/1/23 Analysis and Commentary STEVEN GROSSMAN 3/1/23 Looking Ahead to the Presidents FY24 Budget Request Read More Analysis and Commentary STEVEN GROSSMAN 2/17/23 Analysis and Commentary STEVEN GROSSMAN 2/17/23 What Dr. Califf Told Us During His Fireside Chat Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 7/14/23 Analysis and Commentary STEVEN GROSSMAN 7/14/23 FDA and the Threat of Sequester Read More
Analysis and Commentary STEVEN GROSSMAN 6/30/23 Analysis and Commentary STEVEN GROSSMAN 6/30/23 The State of FY 24 Appropriations: Four Answers to Not-So-Easy Questions Read More
Analysis and Commentary STEVEN GROSSMAN 6/23/23 Analysis and Commentary STEVEN GROSSMAN 6/23/23 Q&A on Senate Appropriations Markup Read More
Analysis and Commentary STEVEN GROSSMAN 6/16/23 Analysis and Commentary STEVEN GROSSMAN 6/16/23 Q&A on House Appropriations Markup Read More
Analysis and Commentary STEVEN GROSSMAN 6/9/23 Analysis and Commentary STEVEN GROSSMAN 6/9/23 Budget Deal Sets Parameters But Many Unknowns Read More
Analysis and Commentary STEVEN GROSSMAN 6/2/23 Analysis and Commentary STEVEN GROSSMAN 6/2/23 The Budget Deal - First Impressions from an FDA Perspective Read More
Analysis and Commentary STEVEN GROSSMAN 5/19/23 Analysis and Commentary STEVEN GROSSMAN 5/19/23 The Macro- and Micro- Budget Processes and Their Impact on FDA Resources Read More
Analysis and Commentary STEVEN GROSSMAN 5/12/23 Analysis and Commentary STEVEN GROSSMAN 5/12/23 FDA and the Iron Triangle of Deficit Reduction Read More
Analysis and Commentary STEVEN GROSSMAN 5/5/23 Analysis and Commentary STEVEN GROSSMAN 5/5/23 Hill Days and the Bumpy FY 24 Appropriations Cycle Read More
Analysis and Commentary STEVEN GROSSMAN 4/28/23 Analysis and Commentary STEVEN GROSSMAN 4/28/23 Top Ten Challenges Facing FDA Read More
Analysis and Commentary STEVEN GROSSMAN 4/21/23 Analysis and Commentary STEVEN GROSSMAN 4/21/23 Q&A About FDA and the FY 24 Budget/Appropriations Process Read More
Analysis and Commentary STEVEN GROSSMAN 4/14/23 Analysis and Commentary STEVEN GROSSMAN 4/14/23 Alliance Testifies to the House and Senate on FY 24 Appropriations Read More
Analysis and Commentary STEVEN GROSSMAN 4/6/23 Analysis and Commentary STEVEN GROSSMAN 4/6/23 FDA’s FY 24 Budget Q&A Read More
Analysis and Commentary STEVEN GROSSMAN 3/31/23 Analysis and Commentary STEVEN GROSSMAN 3/31/23 Why Participate In Hill Days Read More
Analysis and Commentary STEVEN GROSSMAN 3/24/23 Analysis and Commentary STEVEN GROSSMAN 3/24/23 Answers to Your Questions about FY24 Appropriation Read More
Analysis and Commentary STEVEN GROSSMAN 3/17/23 Analysis and Commentary STEVEN GROSSMAN 3/17/23 Alliance Seeks Input on FDA Budget Read More
Analysis and Commentary STEVEN GROSSMAN 3/10/23 Analysis and Commentary STEVEN GROSSMAN 3/10/23 More Details on the Administration’s FDA Budget Read More
Analysis and Commentary STEVEN GROSSMAN 3/3/23 Analysis and Commentary STEVEN GROSSMAN 3/3/23 Looking Ahead to the President’s Budget, Part II Read More
Analysis and Commentary STEVEN GROSSMAN 3/1/23 Analysis and Commentary STEVEN GROSSMAN 3/1/23 Looking Ahead to the Presidents FY24 Budget Request Read More
Analysis and Commentary STEVEN GROSSMAN 2/17/23 Analysis and Commentary STEVEN GROSSMAN 2/17/23 What Dr. Califf Told Us During His Fireside Chat Read More
